DHA omega-3 innovator and maker of the life’sDHA™ brand, Martek Biosciences Corporation (NASDAQ: MATK) announced today that Norman Salem, Jr., Ph.D., Martek’s vice president of research and chief scientific officer, has been selected as the recipient of the Alex Leaf Distinguished Scientist Award for 2010.
Columbia, Md. (Vocus) -- DHA omega-3 innovator and maker of the life’sDHA™ brand, Martek Biosciences Corporation (NASDAQ: MATK) announced today that Norman Salem, Jr., Ph.D., Martek’s vice president of research and chief scientific officer, has been selected as the recipient of the Alex Leaf Distinguished Scientist Award for 2010. The Alex Leaf Award is presented by the International Society for the Study of Fatty Acids and Lipids (ISSFAL) to scientists in recognition of excellence in the research of the health effects of dietary fats, oils and lipids. ISSFAL is the foremost international scientific society dealing exclusively with the health impact of dietary lipids. Dr. Salem was presented the award at the 2010 ISSFAL meeting held May 29 - June 2, in the Netherlands.
“We congratulate Dr. Salem on this honor and recognize him both for his contributions to his field and for his outstanding leadership of Martek’s ongoing research efforts,” said Steve Dubin, Martek CEO.
Dr. Salem is widely recognized as one of the world's leading researchers on docosahexaenoic acid (DHA) and the functions of polyunsaturated fatty acids and lipids. He joined Martek in 2008 after 30 years with The National Institutes of Health (“NIH”) where he led the prestigious Laboratory of Membrane Biochemistry and Biophysics. His scientific work while at NIH included a focus on the role of DHA in neural development as well as on how DHA is made in the body and incorporated into the brain and other organs.
In his role at Martek, Dr. Salem is responsible for leading the company’s clinical research, discovery, microbial biotechnology, and analytical sciences groups and supports the efforts of scientific affairs and medical research. Under his leadership, Martek has made significant progress in expanding the company’s pipeline of new products based on its proprietary microbial biotechnology platform.
Dr. Salem received his B.S. degree in physics from Miami University of Ohio and his Ph.D. in neurobiology from the University of Rochester School of Medicine. During his career, Dr. Salem has published over 200 research articles and book chapters. He was the 2002 recipient of the Supelco/Nicholas Pelick Research Award from the American Oil Chemists Society, which recognizes outstanding original research in fats, oils, lipid chemistry, or biochemistry.
Martek Biosciences Corporation (NASDAQ: MATK) is a leader in the innovation, development, production and sales of high-value products from microbial sources that promote health and wellness through nutrition. The company is the world’s leading provider of algal DHA omega-3 with its flagship product, life'sDHA, a sustainable and vegetarian source of algal DHA omega-3 important for brain, heart and eye health throughout life, for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA™ (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks. Additionally, Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products in major mass, club, drug, grocery and specialty stores and holds leading brand positions in all of its key product categories. For more information on Martek Biosciences, visit http://www.martek.com/. For a complete list of life'sDHA™ or life'sARA™ products, visit http://www.lifesdha.com/. For more information about Amerifit Brands, visit www.amerifit.com.
Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Read the full story at http://www.prweb.com/releases/2010/06/prweb4082214.htm.
Copyright©2010 Vocus, Inc.
All rights reserved